Literature DB >> 16458074

Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.

Kaori Shinoda1, Ke-Qin Xin, Yoshitsugu Kojima, Sukumar Saha, Kentaro Okuda, Kenji Okuda.   

Abstract

Recombinant vaccinia virus-based vaccine combined with DNA vaccine has produced a protective immune response against HIV infection in non-human primates. In this study, we explored the immunogenicity of a recombinant vaccinia virus (LC16m8 strain), which has been used in children without severe side effects. The vaccinia virus expressing an HIV(89.6)env gene (vLC-Env) alone or combined with a DNA vaccine expressing the HIV(89.6)env gene (pCAG-Env) was characterized in BALB/c mice. Vaccination of vLC-Env induced much higher HIV-specific humoral and cell-mediated immune responses than that of pCAG-Env. Priming with pCAG-Env further enhanced vLC-Env induced immune responses, especially cell-mediated immune response. Moreover, efficient expression of Env protein was achieved following infection of bone marrow dendritic cells by vLC-Env in vitro. Administration of vLC-Env-infected dendritic cells to mice generated a high cell-mediated immune response. These results demonstrate that priming with pCAG-Env and boosting with vLC-Env represents a logical candidate for vaccination against HIV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458074     DOI: 10.1016/j.clim.2005.12.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  3 in total

1.  Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice.

Authors:  Hongli Zhou; Li Guo; Min Wang; Jianguo Qu; Zhendong Zhao; Jianwei Wang; Tao Hung
Journal:  Virol J       Date:  2011-01-05       Impact factor: 4.099

Review 2.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 3.  New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.

Authors:  Takehiro Ura; Akio Yamashita; Nobuhisa Mizuki; Kenji Okuda; Masaru Shimada
Journal:  Vaccine       Date:  2020-11-24       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.